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Abstract
There is substantial hospital-level variation in the quality of healthcare delivered in the
United States. Although patients now have greater access to public reporting of hospital
quality than ever before, many individual, geographic, and structural factors limit patient
choice. The degree to which hospital quality aligns with hospital market share is largely
unknown.
Using public performance measure score and volume data from CMS’s Hospital Care
Compare, we assessed the association between publicly reported hospital performance
scores and hospital market share for elective, semi-elective, and non-elective procedures.
Using logistic regression, we found a significant association between hospitals’ riskadjusted complication rate and their market share with a modest effect size for hip/knee
replacement complication (-4.2; 95% CI: -6.56, -1.88; p<.001) and acute myocardial
infarction (AMI) readmission (-1.7; 95% CI: -3.10, -0.25; p=0.02). We did not find a
significant association for AMI mortality or coronary artery bypass graft (CABG)
readmission or mortality.
These findings highlight a continued need to better align where patients receive care and
the quality of care they receive for non-elective and semi-elective conditions/procedures.
They support efforts to increase transparency and usability of hospital quality reporting,
reduce constraints on patient choice, and increase the capacity and geographic
distribution of high-quality hospitals.
Value-based payment and healthcare delivery models are essential to efforts to advance
the alignment of hospital quality and market share given their incentives around clinical
outcomes. Expanding the implementation of these models could improve access to highquality care. However, early evidence suggests that the structure of many of these
programs may disincentivize providers from caring for more complex patients and
worsen existing racial and socioeconomic health disparities, indicating an urgent need for
refinement and optimization.
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1.0 Introduction
Twenty years after the publication of “Crossing the Quality Chasm: A New Health
System for the 21st Century,” there remains substantial hospital-level variation in the
quality of healthcare delivered in the United States1,2. A 2016 study found a massive 1.7
to 32-fold difference over 24 AHRQ outcome measures between hospital service areas
and counties in the top and bottom 10%1. Regional variation in outcomes does not appear
to be associated with healthcare spending or utilization3,4.
Studies have consistently shown that hospital and physician quality of care is important
to patients5,6. A 2005 study of 16 heterogenous focus groups across four cities found
patients to be highly interested in hospital quality and would consider switching hospitals
based on quality information5. Other studies have further demonstrated patient
willingness to switch hospitals based on surgical mortality data7. Of the various
dimensions of healthcare quality, technical quality of the physician appears to be
particularly important to patients, although interpersonal and experience-based skills are
valued as well8.
There are many public tools available to help patients make informed decisions about
where to seek care9. For example, the Center for Medicare and Medicaid Services (CMS)
developed the Hospital Care Compare online tool (previously known as Hospital
Compare) to enable people with Medicare to “make more informed decisions about
where [to] get [their] health care”10. The site lists hospital-level risk-adjusted
readmission, mortality, and complication performance measure scores for a number of
conditions and procedures, including acute myocardial infarction (AMI), coronary artery
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bypass graft (CABG), and hip/knee replacement (Image 1). Categorical rating
classifications are also presented for each performance measure, indicating whether the
score is no different than the national average, above the national average, or below the
national average.
There are also numerous other national-level online rating tools for patients to access
including the US News & World Report, Healthgrades, Consumer Reports, Consumer
Checkbook, and ProPublica9. Healthgrades is the most-accessed overall site with 8.9
million unique visitors in September 20159. CMS’s Hospital Compare and Physician
Compare is the most-accessed public site with 3.7 and 5.3 million unique views
respectively in 20159. Private hospital rating sites often incorporate CMS’s public
hospital rating data.
Individual, Geographic, and Structural Factors Limiting Quality-based Choices
Studies have demonstrated that the degree to which the public can access, understand,
and act on hospital quality information can be limited and uneven. One 2015 survey
found that only 17% of respondents had seen any information comparing hospital quality
and only 4% had used what they found11. Even with adequate access, hospital quality
data can be challenging for consumers to understand12. Research has revealed some best
practices for how to present the information with particular focus on message route and
tone as well as how best to improve the comprehension of those with low numeracy
skills13,14. Even still, differences in consumers’ decision-making strategies lead to
substantial variation in the effect of publicly reported performance measures at the
individual level15.
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Even with adequate access and understanding of comparative information, patient choice
may be restricted by geographic, socioeconomic, and structural factors. These factors
may be best illustrated in rural contexts where research has shown a tendency for patients
to bypass nearby rural hospitals to receive care at larger urban centers16. However, this
tendency is unevenly distributed. One study of rural areas in Colorado found that patients
with Medicare and Medicaid were 43.6% and 20.9% less likely to bypass rural hospitals
than patients with commercial insurance17. Furthermore, rural white female patients were
found to go to urban hospitals 5.76 times more than nonwhite female patients17. Another
study of a sample of 1,702 rural Medicare hospitalizations found that white race and high
education status were associated with choosing an urban hospital over a rural hospital18.
Studies applicable to the non-rural areas of the United States have confirmed these
observations. Within select condition types and procedures, privately insured patients and
those in HMO’s have been found to be more responsive to hospital quality measures,
relative to Medicaid, Medicare, and non-HMO commercially insured patients19,20.
The hospital network of individual insurance plans has a large impact on patients’ ability
to choose where to receive care as well. The McKinsey Center for U.S. Health System
Reform found that roughly 40% of marketplace hospital networks were considered
“narrow” in 2014, 2015, and 2016—“narrow” was defined as having less than 70% of
hospitals in a given area participating21. The Kaiser Family Foundation estimated that in
2015 one-third of Medicare Advantage enrollees were in plans with narrow physician
networks, defined as covering less than 30% of physicians in the county22. Furthermore,
20% of Medicare Advantage plans were found to include fewer than five cardiothoracic
surgeons and 36% of plans had fewer than 10% of psychiatrists in their county in 201522.
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Narrow network insurance plans do offer some advantages to consumers. One study
estimated that plans with narrow physician and hospital networks were approximately 16
percent cheaper relative to plans with broader networks23. In addition, narrow networks
could help steer patients towards high-value providers24. However, they also carry risks
by limiting provider choice and increasing financial liability to patients should they need
to seek care from an out-of-network specialist. It is also often difficult for patients to
assess whether a narrow network includes high-quality providers and is adequate for their
needs24.
The fact that some groups of patients have more choice than others has important social
ramifications. Many racial and socioeconomic disparities in clinical process measures
and health outcomes have been linked to greater use of poorer performing hospitals by
minority or marginalized populations. One large national study of Medicare patients
found that between 2006 and 2008 black patients were more likely to be readmitted after
hospitalization for AMI, CHF, and pneumonia and that that gap was partially explained
by site of care25. A single market study of very preterm infants in New York City
hospitals found that hospital of birth accounted for approximately 40% of the disparity
between black and white patients in morbidity and mortality and for approximately 30%
of the disparity between Hispanic and white patients26. Notably, research also suggests
that the differences in site of care between black and white patients is primarily driven by
non-geographic factors (e.g. socioeconomic status, provider bias, hospital access) than by
distance alone27. One study found that such non-geographic factors accounted for a
greater degree of the difference in use of high-quality hospitals for AMI and CABG by
black and white patients than geographic factors27.
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The Gap in the Assessment of the Alignment between Hospital Quality and Market Share
As previously detailed, there are many forces within healthcare in the United States that
either promote or constrain patients’ ability to choose to receive care from high quality
hospitals. However, a robust, multi-condition, nation-wide assessment of the aggregate
effect of these forces is missing from the literature.
For some conditions and procedures, substantial research efforts have explored the
relationship between surgeon and institution volume and outcomes28,29. However, these
studies are designed to assess how greater operator experience could be associated with
better outcomes. They are not designed to assess market dynamics or the overall
utilization of higher-quality hospitals by patients.
One study in 2003 did examine whether public mortality scores impacted hospital market
share and found that higher mortality in a number of conditions did not adversely impact
market share30. However, this study was limited to 30 hospitals within one healthcare
market in Ohio and used data that is now over twenty years old30.
Furthermore, a robust assessment of the geographic distribution of high-quality hospitals
in United States and the degree to which patients have meaningful condition-specific
choices within their markets is also missing from the literature.
A 2017 study examined degree of clustering of high-quality health service centers in US
healthcare markets using the Dartmouth Atlas’s hospital referral region (HRR) definition
of healthcare markets and CMS’s five star rating system31. The study found that
healthcare markets rarely had high quality performance in all of the four healthcare
sectors of hospitals, nursing homes, home health agencies, and dialysis centers. It also
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demonstrated that HRRs that did have 3 or 4 top-ranked health sectors had a higher
median income, lower percent of the population living below the poverty line, and lower
percent of the population that was Black relative to HRR’s without any top-ranked health
sectors31. This study was limited by its use of CMS’s overall five-star rating system as it
precludes conclusions about the condition-specific choices that are made at the patient
level. A 2016 National Bureau of Economic Research working paper found little
correlation across quality measures within hospitals, underscoring the need to use
condition-specific quality measures when assessing patient choice32.
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2.0 Statement of Purpose
It is in this context that this study aims to investigate the relationship between publicly
reported hospital performance scores and hospital market share using publicly available
fee-for-service Medicare hospital volume and quality data.
By using quality data that is accessible by patients online through CMS’s Hospital Care
Compare tool, this study hopes to shed light on the relative degree to which patients are
able to choose to receive care from high quality providers for elective, semi-elective, and
non-elective conditions and procedures.
This study also aims to present preliminary data regarding the number and market-level
distribution of condition-specific, high-performing hospitals to explore the practicality of
the market-level choices that consumers are presented with from CMS’s Hospital Care
Compare website.
Results from this study could support efforts to promote patient choice within healthcare
in the United States, improve the utility of existing methods to assess and report hospital
quality to the public, increase the performance of low-quality hospitals, and expand the
implementation of value-based models of care.
Specific Aims
Specific Aim 1: This study aimed to assess the association between publicly
reported hospital performance scores and hospital market share for elective
(Hip/Knee Replacement), semi-elective (CABG), and non-elective (AMI)
conditions/procedures in Hospital Care Compare.
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Hypothesis 1: Given the structural barriers that inhibit patient choice, it was
hypothesized that this study would not find an association between publicly
reported hospital performance scores and hospital market share.
Specific Aim 2: This study aimed to assess the number of healthcare markets
(HRRs) that have hospitals that are rated as “above the national average” by CMS
for elective (Hip/Knee Replacement), semi-elective (CABG), and non-elective
(AMI) conditions/procedures in Hospital Care Compare.
Hypothesis 2: It was hypothesized that this study would find that very few
markets have hospitals that are rated as “above the national average” for elective
(Hip/Knee Replacement), semi-elective (CABG), and non-elective (AMI)
conditions/procedures in Hospital Care Compare.
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3.0 Methods
3.1 Student Contribution & Ethics Statement
The author August Oddleifson was primarily responsible for and completed all stages of
the research design and implementation process, including research design, data analysis,
and manuscript drafting. Other co-authors of the Oddleifson et. al. 2021 paper in JAMA
Network Open contributed to various aspects including study concept and design,
interpretation of data, data analysis, and manuscript editing and feedback.
This research was exempt from institutional review board approval because it did not
meet the NIH’s definition of human subject research outlined in 45 CFR part 46.
Animals were not used at part of this study.

3.2 Methods Description
Temporal Structure
This study was cross-sectional and conducted at the hospital-level. It used three
conditions/procedures that were chosen to exemplify non-elective, semi-elective, and
elective conditions/procedures: acute myocardial infarction (AMI), coronary artery
bypass graft (CABG), and hip/knee replacement, respectively. The 30-day mortality rate
and the 30-day readmission rate were used for AMI and CABG and the 90-day
complication rate was used for hip/knee replacement. All performance scores and volume
measurements were obtained from CMS’s Hospital Care Compare database. Hospital
condition/procedure-specific volume was obtained from the 2020 report year,
corresponding to the period of July 1, 2016 to June 30, 2019. Hospital
9

condition/procedure-specific performance scores were obtained from the 2019 report
year, corresponding to the period of July 1, 2015 to June 30, 2018. The market share was
computed at the hospital referral region (HRR) level by dividing hospitals’
condition/procedure-specific volume by the sum of their condition/procedure-specific
volume in their HRR.
Covariates
The hospital characteristics of geographical region, ownership, type, and critical access
designation were obtained from the Hospital Care Compare database. The hospital
characteristics of teaching status, bed size, and healthcare referral region (HRR) were
obtained from the Dartmouth Atlas. All hospital characteristics correspond to calendar
year 2016.
The American Community Survey 2012-2016 5-year estimate was the source for ZIP
Code Tabulation Area (ZCTA) demographic characteristics which were aggregated to the
HRR level. These demographic characteristics included population size, percent nonwhite, percent population in a rural area, percent population with less than a high school
education, and percent of population below the federal poverty level.
All continuous covariates were included as categorical terciles in each regression model.
Market concentration was calculated by condition/procedure for each HRR by the
Herfindahl-Hirschman Index (HHI) method33.
A ZCTA to zip code crosswalk was required to link each ZCTA to an HRR. The
crosswalk used was from the American Academy of Family Physicians’ Uniform Data
System Mapper website34.
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Exclusion Criteria
Prior to the application of the exclusion criteria, there were 4,930 hospitals for each of the
five performance measures. The hospital type criteria excluded 96 Children’s or
Veteran’s Association hospitals. The state exclusion criteria excluded 59 hospitals in
Puerto Rico, Guam, American Samoa, Virgin Islands, and the Northern Mariana Islands.
2,689 hospitals did not have a volume or score available for the AMI Readmission
measure. 2,527 hospitals did not have a volume or score available for the AMI Mortality
measure. 3,804 hospitals did not have a volume or score available for the CABG
Readmission measure. 3,795 hospitals did not have a volume or score available for the
CABG Mortality measure. 2,115 hospitals did not have a volume or score available for
the Hip and/or Knee Complication measure. An additional 259 hospitals were missing at
least one covariate.
Performance Measures
The performances measures in this study included fee-for-service Medicare beneficiaries
65 or older who had been enrolled for 12 months or more before their date of admission.
The readmission measures also required the patients to be enrolled for at least 30 days
after their discharge for inclusion. The mortality measures included deaths for any reason
either during or after the hospital admission. The CABG measure only included patients
who underwent isolated CABG without concomitant valve replacement or any other
major vascular or cardiac procedure. Complications that were included in the hip and/or
knee replacement measure included any of the following: pneumonia, acute myocardial
infarction, or sepsis/septicemia/shock during the index admission or within 7 days of
admission; pulmonary embolism, surgical site bleeding, or death during the index
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admission or within 30 days; or mechanical complications or periprosthetic joint
infection/wound infection during the admission or within the following 90 days. All
performance measure underwent risk adjustment by CMS to account for various patient
characteristics including age and past medical history35.
CMS calculated the performance score categorical ratings by comparing the national rate
with the hospital’s 95% interval estimate36. If the 95% interval estimate included the
national rate than the hospital was labeled as “no different than the national rate.” If the
95% interval estimate was higher than the national rate than the hospital was labeled as
“worse than the national rate.” If the 95% interval estimate was lower than the national
rate than the hospital was labeled as “better than the national rate.”
These five performance measures were chosen by this study because they are used widely
by healthcare policy researchers and are readily accessible for access by patients on the
CMS Hospital Care Compare website.
The performance score was centered at the sample mean for this study.
A Note on the Choice of Use of HRRs over HSAs
Markets are difficult to define. However, prior research has shown that for 45% of HSAs,
fewer than half of the patients were admitted to hospitals located within the HSA37. In
contrast, on average, 88% of patients were admitted to hospitals located in their HRR37.
Therefore, conceptually we believe using HRR will allow us to better understand
patients’ choice of hospitals and examine changes in a hospital’s market share.
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3.3 Statistical Methods
The statistical test used to model hospital market share was a fractional regression via
generalized linear models with binomial family and logit link. A separate model was used
for each of the five performance measures. The response variable was hospital market
share and the primary predictor variable was performance measure score. Covariates
included the hospital characteristics of number of beds tercile, ownership, and teaching
status; the market non-demographic characteristics of HRR concentration and geographic
region; and the market demographic characteristics of population size tercile, percentage
non-white tercile, percentage rural tercile, percentage less than high school degree tercile,
and percentage below federal poverty line tercile. The lowest tercile served as the
reference level for all tercile variables. All model estimates were reported as marginal
effects. Estimates included the 95% confidence interval. Significance was determined by
a P<.05. All analysis was completed in RStudio, version 1.2 by August Oddleifson.
A Note on the Choice of Fractional Regression over Simple Linear Regression
We explored the use of a simple linear model early in our research. It produced a
substantial number of market share predictions outside of 0 to 1, which is inappropriate
for a proportional-based response variable. Table 1 and Figure 1 summarizes the large
percentage of predictions that fell below 0. Based on this evaluation, we considered
fractional regression to be more appropriate for our analysis and chose not to report
results from a simple linear model.
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4.0 Results
Characteristics of Hospitals
Table 1 in Oddleifson et. al. (2021) shows the diverse characteristics of hospital in the
sample38. In total, 1,989 and 2,165 hospitals were included for AMI readmission and
mortality respectively, 966 and 975 for CABG readmission and mortality, and 2,660 for
hip and knee complication38.
Table 1 in Oddleifson et. al. (2021) shows that hospitals represented in the hip and knee
complication measure tended to have a lower market share compared to AMI and CABG.
Specifically, the average market share for hip and knee complication was 5.2% whereas it
was 7.3% and 6.8% for AMI readmission and mortality respectively and 21.2% and
20.9% for CABG readmission and mortality respectively38. Moreover, the CABG
measures had many hospitals with market shares above 75% while the hip and knee
measure had relatively few.
The unweighted mean of the performance measure score was 15.7% with a standard
deviation of 1.0% for AMI readmission, 12.8% with a standard deviation of 1.1% for
AMI mortality, 12.8% for CABG readmission with a standard deviation of 1.3%, 3.1%
for CABG mortality with a standard deviation of 0.9%, and 2.6% for hip/knee
complications with a standard deviation of .6%.
Performance Score and Market Share Regression Result
Table 2 in Oddleifson et. al. (2021) summarizes the adjusted and unadjusted results of the
multivariable regression assessing the association between hospital-level performance
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score and market share. Table 2 in this thesis includes the adjusted marginal effect results
of the covariates. The hip and knee complication model showed that every percentage
point increase in risk-adjusted 30-day complication rate was associated with a 4.2
percentage point decrease in market share (95% CI, −6.56 to −1.88 percentage points;
standardized coefficient: −0.25; P < .001)38. The AMI readmission model showed that
every percentage point increase in a hospital’s risk-adjusted complication rate was
associated with a 1.7 percentage point decrease in its market share (95% CI, −3.10 to
−0.25; standardized coefficient, −0.16; P = .02)38. There was no significant association
between a hospital’s performance score and market share for AMI mortality (−0.85; 95%
CI, −2.07 to 0.38; standardized coefficient, −0.09; P = .17), CABG readmission (−0.49;
95% CI, −2.49 to 1.52; standardized coefficient, −0.04; P = .63), and CABG mortality
(−1.24; 95% CI, −4.40 to 1.93; standardized coefficient, −0.06; P = .44)38.
Number and Market-Level Distribution of Above-Average Hospitals
Table 3 in this thesis shows that the vast majority of markets did not have a hospital rated
as ‘better than the national average.’ Eighty-five percent of markets did not have a
hospital that was ‘better than the national average’ for the AMI Readmission measure,
86% for the AMI Mortality measure, 70.8% for the CABG Readmission measure, 69.2%
for the CABG Mortality measure, and 80.1% for the Hip and Knee Complication
measure.
Similarly, the vast majority of hospitals were contained within markets that do not have a
hospital listed as ‘better than the national average.’ Ninety-two percent of hospitals were
within a market that did not have a hospital listed as ‘better than the national average’ for
the AMI Readmission measure, 82.9% for the AMI Mortality measure, 89.7% for the
15

CABG Readmission measure, 82.9% for the CABG Mortality measure, and 73.9% for
the Hip and Knee Complication measure.
Furthermore, the vast majority of patient volume was contained within markets that do
not have do not have a hospital listed as ‘better than the national average.’ Ninety-one
percent of patient volume occurred within a market that did not have a hospital listed as
‘better than the national average’ for the AMI Readmission measure, 81.8% for the AMI
Mortality measure, 87.2% for the CABG Readmission measure, 79.3% for the CABG
Mortality measure, and 67.8% for the Hip and Knee Complication measure.
Table 4 in this thesis shows that the vast majority of markets for all five measures only
contain average-rated hospitals. Eighty-three percent of markets only contained average
rated hospitals for the AMI Readmission measure, 80.7% for the AMI Mortality measure,
66.9% for the CABG Readmission measure, 66.2% for the CABG mortality measure, and
69.0% for the Hip and Knee Complication measure.
Figures 2-6 show how large contiguous areas of the United States consist of markets
without ‘better than the national average” hospitals for all five performance measures.
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5.0 Discussion
5.1 Looking Back: Understanding the Results
Better hospital performance score was associated with a larger market share for hip-knee
replacement complication rate and AMI readmission rate but not for AMI mortality,
CABG readmission, or CABG mortality. The effect sizes for the significant associations
were modest. The greater effect size for the elective procedure suggests that patients may
be more able to choose their place of care for elective procedures relative to semi-elective
and non-elective procedures.
There are four major factors that can contribute to an explanation of the differences
observed in these results: elective vs non-elective procedure type, geographical
accessibility, consolidation of hip/knee replacement procedures into high-volume centers,
and the surgical quality-volume relationship.
Elective vs Non-Elective Procedure Type
The clearest explanation for these findings is that hip and knee replacement is an elective
procedure that allows patients more time and opportunity to choose the site of care
relative to the semi-elective CABG or the emergent AMI. Patients who value quality
could more easily chose higher quality hospitals.
If patients can more readily chose site of care for elective procedures, one could assume
that the competition for patients could drive providers to improve the quality of care.
Interestingly, this assumption was found to be unsupported in a 2016 National Bureau of
Economic Research study that showed no association between a measure of market-level
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competition and quality for elective hip and knee replacement32. Like this study, the
authors proposed several explanations including low use of publicly reported quality
measures and reliance on primary care physician referral by patients32.
Geographic Accessibility
For CABG, the lack of association may suggest that consumers are less able to choose
their site of care based on public reporting of hospital quality due to the fewer number of
CABG facilities. There is a substantial difference in the number of centers providing hip
and knee replacement (~2630) vs CABG (~970) in the United States. This may mean that
CABG centers are more geographic dispersed than hip and knee replacement centers.
Several studies provide preliminary evidence that patients may have greater geographic
proximity to high-quality hip and knee replacement centers than high-quality CABG
centers. A 2016 study found that 82% of the US population lived within 50 miles of a
high-volume center for hip and knee replacement39. A 2017 study found that more than
40% of older adults lived greater than 50 miles from a hospital with a STS-CABG
ranking better than their closest hospital, indicating a substantial travel distance in pursuit
of better quality40. Notably, for CABG, increased driving time to a cardiac care center has
been shown to independently worsen 30-day outcomes from cardiac operations41.
The Consolidation of Hip/Knee Procedures into High-Volume Centers
Our data showed that the mean complication rate for the hip/knee replacement measure
(2.6%) was much lower than the mean readmission and mortality rates for AMI (15.7%
and 12.8% respectively) and the readmission rate for CABG (12.8%).
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This low complication rate for hip and knee replacement is consistent with national
efforts to improve procedural outcomes and reduce the variation between centers. Central
to the success of this effort has been the reduction in the use of low-volume centers.
Between 2000 and 2012, the proportion of arthroplasties performed in low-volume
centers decreased from 17.4% to 5.4%39. As described in the next section, high-volume
centers tend to perform better due to the hypothesized relationship between operator
volume and outcomes in hip/knee replacement. The alignment observed in our study may
be partly explained by these national trends in volume consolidation.
It is important to note that the beneficial impact of this alignment between volume and
quality in hip/knee replacement is distributed unevenly among patient populations.
Research has demonstrated that minority populations have lower hip/knee replacement
utilization rates and higher incidence of adverse events42. Part of these differences may be
explained by greater utilization of low-volume hospitals by minorities. A 2008 study
found Black, Hispanic and Asian race/ethnicity and Medicaid insurance to be predictors
of utilization of low-volume hospitals for total knee replacement43. A 2011 study found
Hispanic ethnicity, and black and Asian race to be predictors of low-volume hospital use
for total hip replacement44.
The Quality-Volume Relationship
There is extensive literature exploring a possible causal relationship between surgical
volume and quality28,29,45. The mechanism is that surgeons and surgical centers that
perform more surgeries have accumulated more individual and institutional experience
that benefits patients through better outcomes. The effect is not uniform across surgical
procedures46. For hip and knee replacement, surgeon and hospital volume has been
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shown to be associated with lower mortality and readmission, though process
standardization has also been shown to be independently associated with better
outcomes47,48. In contrast, for coronary artery bypass graft (CABG), volume has been
shown to be a poor overall predictor of mortality49-51. And for acute myocardial infarction
(AMI), higher volume centers are associated with better adherence to process of care
measures but not with better outcomes52,53.
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5.2 Looking Forward: Patient Choice, Value-Based Care, and Health
Equity
While the observed significant associations between performance score and market share
for AMI readmission rate and hip and knee replacement were encouraging, the small
effect size highlights a continued need to increase the number of patients being treated at
high-quality hospitals. This thesis proposes that there are two principal means to pursue
this goal: (a) improve patients’ awareness of and ability to use and act on hospital quality
ratings and (b) increase the number, capacity, or geographic accessibility of high-quality
hospitals.
This section will explore specific unmet needs in these two areas and discuss how best to
refine and optimize existing policy interventions.
Improving Public Reporting of Quality to Promote Patient Choice at both the Hospital
and Health Plan Level
This study identified a major limitation in CMS’s Hospital Care Compare data set and
public website. For the five performance measures we examined, CMS Hospital Care
Compare does not present most consumers with meaningful choices within their markets.
When a consumer in most healthcare markets in the United States visits the Hospital Care
Compare website to find information about the quality of the hospitals in their area for a
specific condition or procedure, they learn that all the hospitals are of similar quality—no
different than the national average. Without doubt, discerning differences in quality
between hospitals is a challenging science. However, this research demonstrates a need to
improve existing evaluation methodologies or create new approaches that enable the
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presentation of more meaningful differences to consumers at the market level in an effort
to better inform their choices.
Improving hospital quality reporting at the health plan level is also an urgent need. A
substantial degree of hospital choice takes place during health plan selection54. Initiatives
to improve the transparency of hospital quality reporting must be accompanied by
renewed efforts to report network-wide quality at the point of consumer plan decision in
the healthcare exchange marketplaces. Selecting health insurance is a notoriously
difficult process, especially for consumers with low health literacy or impaired decision
making55. Lack of understanding of concepts, poor skill with numbers, information
overload, misinformation, time constraints, and language barriers are a few of the
challenges consumers face when selecting a plan56-58. Studies have shown that health
insurance literacy is lower among vulnerable populations, such as those with low income
or low education56,59,60. It is therefore imperative to find intuitive, meaningful, and
accurate ways to represent aggregate health insurance network quality information within
health insurance marketplace exchanges.
An excellent case example of the challenges associated with health plan rating systems is
Medicare Advantage. Medicare Advantage is a managed-care Medicare program offered
through various private insurers. It has a 5-point star rating system that incorporates more
than 50 measures around clinical effectiveness, accessibility, patient experience, and
health outcomes61. Much like Hospital Compare, these ratings are available through an
online platform, along with each plan’s premiums, deductibles, copays, and drug costs61.
However, few eligible consumers know about the star rating system and many find the
website hard to use62. While studies have shown that consumer choice of Medicare
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Advantage plans is associated with quality and cost, brand recognition and market share
continue to exert a strong influence63,64. Efforts within the Medicare Advantage program
to provide transparent quality reporting are laudable but additional work is needed to
finetune the approach to truly enable consumers to drive quality improvement.
Using Public Reporting to Incentivize Improvements in Hospital Quality & Health
Outcomes
Many studies have explored the role of public reporting of hospital quality data in
incentivizing hospital care quality improvement. A meta-analysis in 2016 found that the
introduction of public reporting of hospital quality data was associated with a reduction
in mortality rates65. Research has also demonstrated steady improvement in patient
satisfaction nationally after the introduction of the Hospital Consumer Assessment of
Healthcare Providers and System (HCAHPS) survey measuring patient satisfaction66.
Qualitative narrative analysis in Rhode Island has also shown that public reporting of
patient satisfaction can accelerate quality improvements at hospitals67.
There are several mechanisms that have been proposed to explain the positive impact of
public reporting of hospital quality data on patient satisfaction and health outcomes.
Berwick et. al. (2003) proposed two pathways: the selection pathway and the change
pathway68. The selection pathway represents how providers may be motivated to improve
their services with the knowledge that consumers are actively selecting providers based
on the publicly available information. This pathway aligns with the concept of a free
market—where providers are incentivized to meet the needs of consumers or risk losing
market share to competitors. The change pathway represents how providers may be
inherently motivated to improve if deficits in their processes are made known to them.
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Hibbard et. al. (2005) proposed a third mechanism wherein providers identified as poor
performers would be motivated to improve to protect their reputation69.
A risk inherent in the use of public reporting of hospital quality data is intentional patient
selection bias. Hospitals could be motivated to avoid more challenging or high-risk
patients to achieve quality benchmarks70,71. A survey conducted in 2005 of interventional
cardiologists found that 79% agreed that public reporting of mortality data had influenced
their decision whether or not to conduct angioplasty on individual patients72. A 2005
study comparing utilization of PCI in higher-risk patients found lower utilization in New
York, a state with public PCI outcomes reporting, and Michigan, a state without public
PCI outcomes reporting73. It is important to note that more is not always better—perhaps
public reporting leads interventionalists to be more likely to defer a case when the
complexity exceeds their capability71.
Refining Innovative Value-Based Payment and Healthcare Delivery Models:
Opportunities for Alignment and Risks for Health Equity
Innovative healthcare delivery models that promote high-value care are essential to
efforts to further align hospital quality and hospital market share because their incentive
structures are explicitly oriented around clinical outcomes. Greater adoption of valuebased care models would likely increase accessibility to high-quality care.
However, there is a risk that these models will disincentivize providers from treating
more medically or socially complex patients, which could worsen access and outcome
disparities. In implementing these programs, care must be taken to adequately mitigate
this risk.
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This section will explore several promising innovative models—bundled payments,
value-based purchasing, Medicare Advantage, and value-based insurance design—and
offer a review of the current evidence for their effectiveness in improving care value,
health outcomes, and health equity.
Bundled Payments
Bundled payment reimbursement models provide a single payment for the entirety of a
clinical episode. CMS has conducted several large scale trials of bundled payments,
including Bundled Payments for Care Improvement (BPCI), BPCI Advanced, and the
Comprehensive Care for Joint Replacement Model (CJR)74.
Research has shown that bundled payments can achieve similar or better outcomes
compared to fee-for-service with modestly lower cost for lower extremity joint
replacement but not for other conditions or procedures75-77. Specifically regarding CABG
and PCI, a recent study demonstrated participation in BPCI was not associated with a
meaningful differences in length of stay, clinical outcomes, or payments for either
procedure78.
Unfortunately, the benefit of CJR for hip and knee replacement was not evenly
distributed. A recent study of over four million Medicare beneficiaries between 2013 and
2017 found that the implementation of the CJR model for hip and knee replacement was
associated with a modest increase in utilization disparities in total knee replacement but
not total hip replacement79.
The difference in the performance of joint replacement and PCI under bundled payments
may be due to the fact that post-acute care costs, with higher variation in joint
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replacement, may be more easily optimized than readmission costs, which have higher
variation in acute myocardial infarction78,80. Additionally, Agarwal et. al. 2020 notes that
the difference in impact of bundled payments on joint replacement versus medical
conditions may be partly explained by the elective nature of joint replacement and the
younger, less medically complex patient population77.
In the context of the results of this thesis, it appears that bundled payments may play a
role in improving quality of hip and knee replacement and thus could increase geographic
access to high quality providers. However, the observed modest worsening of utilization
disparities is concerning. More rigorous risk stratification of patients could enable to
more appropriate compensation and reduce the incentive for a selection bias77,81,82.
The BPCI Advanced model is ongoing and will provide more data on the impact of
bundled payments on quality and cost83.
Medicare Advantage
Most private insurers that provide Medicare Advantage health insurance plans receive
risk-adjusted capitated payments from the federal government for each plan enrollee,
providing a clear incentive for insurers to facilitate high-value care and reduce cost84.
Other notable characteristics of Medicare Advantage include how they limit out-ofpocket spending, provide prescription-drug coverage, and often offer additional services
such as health rewards programs and targeted services for at-risk patients84.
However, despite the clear incentive structure, results are mixed as to whether Medicare
Advantage is superior to Traditional Medicare in value of care and outcomes measures.
One recent study using Medical Expenditure Panel Survey data from 2006 to 2015 found
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that the prevalence of low-value care use was similar between Medicare Advantage and
Traditional Medicare85. Furthermore, another study found that risk-adjusted 30-day
readmission rates for acute myocardial infarction, congestive heart failure, and
pneumonia were higher for Medicare Advantage enrollees compared to those with
Traditional Medicare86. However, several studies have shown overall healthcare
utilization to be lower for Medicare Advantage enrollees compared to Traditional
Medicare without impacting health status or patient satisfaction87,88. More research is
needed to resolve this conflicting picture. The heterogeneity of the services and benefits
offered by Medicare Advantage plans is a clear challenge that studies need to actively
mitigate in their design.
Some evidence suggests that the incentive structure inherent in Medicare Advantage
plans enrollees may not be appropriate optimized and may be contributing to worsening
health disparities. Three recent studies revealed that there are greater racial disparities in
hospital readmission, avoidable hospitalizations, and behavioral health process measures
within Medicare Advantage enrollees relative to Traditional Medicare enrollees89-91.
Furthermore, another study found that Medicare Advantage plans with higher star ratings
had larger disparities in quality92. While it is well documented that minority patients are
more likely to receive lower quality hospital care and less likely to have access to highquality primary care, the mechanisms at play for why specific outcomes disparities are
worse for Medicare Advantage enrollees relative to Traditional Medicare enrollees is still
unclear89. However, their existence supports adoption of standardized plan-level
reporting of outcome measures stratified by race and ethnicity91. There may also be value
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in refining the risk-adjustment methodology of the Medicare Advantage star ratings in
order to lessen incentives for insurers to avoid more challenging patient populations93.
Another important structural component of Medicare Advantage plans is that they specify
a defined network of hospitals and providers for enrollees to use and are sold on
marketplace exchanges84. This essentially requires patients to choose their providers at
the time of health plan selection. Unfortunately, current evidence does not indicate that
this increases the overall likelihood that patients will receive care at high-quality
hospitals relative to Traditional Medicare94. As detailed in the above section “Improving
Public Reporting of Quality to Promote Patient Choice,” quality reporting at the health
plan level needs optimization to improve transparency and facilitate more informed
choices by patients.
One additional area of opportunity is Medicare Advantage plans that are offered by
healthcare service organizations directly. Referred to as “vertical integrated”, these plans
tend to have higher patient satisfaction and perform better on provider process
measures95,96. Yet, the vast majority of Medicare Advantage enrollees are not enrolled in
vertically integrated plans—only 22.0 percent of contracts were vertically integrated in
201595.
Value-Based Purchasing Programs
Value-based purchasing (VBP) programs adjust fee-for-service payments to acute care
hospitals based on clinical performance97. Pay-for-performance VBP is a relatively lowrisk introductory value-based care model that allows providers and organizations to build
competence in key areas such as performance measurement, payment incentives, and risk
management98. CMS’s VBP program, Hospital Value-Based Purchasing Program
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(HVBP), began in 2013 and adjusts payments based on clinical outcomes, person and
community engagement, safety, efficiency, and cost reduction97. Numerous other VBP
programs exist, implemented by both state and commercial payers98.
Unfortunately, the most recent meta-analysis of CMS’s HVBP showed no impact on
patient outcomes or quality of care99. However, this analysis only included seven
academic papers, indicating that the impact of this program may not be adequately
explored in the literature. More specifically, research in this area is limited by short study
periods98. There is also limited understanding of exactly how providers and hospitals
respond to the value-based incentive structures and the levers they use to improve care
quality98.
A meta-analysis of 28 studies showed that safety-net hospitals tended to perform worse
on the outcome measures that underline the payment adjustment calculations, indicating a
possible disproportionate negative impact on safety-net hospitals99. This finding supports
efforts to more rigorously adjust for patient population-level risk factors to ensure that
safety-net hospitals are not unfairly punished and that non-safety-net hospitals are not
further disincentivized from caring for more socially complex patients99.
Value-based purchasing programs likely have an important role to play in aligning
hospital quality and hospital market share. However, additional research is needed to
understand more precisely how the incentives interact with the underlying hospital-level
mechanisms and how patient-level social and medical complexity can be adequately
adjusted for to avoid detrimental selection incentives.
Value-Based Insurance Design
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Value-based insurance design (VBID) adjusts cost-sharing with consumers based on the
value of the provided service. Out-of-pocket spending is higher for low-value care than
for high-value care100. VBID has been implemented by both private and public insurers,
including the states of Connecticut and North Carolina101,102. Medication adherence is a
particular focus of these programs due to VBID’s capacity to reduce the out-of-pocket
cost of medications for diabetes, hypertension, and cholesterol that have the potential to
prevent disease or significantly impact disease trajectory100.
The most recent meta-analysis of experimental studies assessing the impact of VBID on
medication adherence, clinical outcomes, and total health care spending showed that
VBID was associated with increased medication adherence without increased total health
care spending100. The meta-analysis cited limited evidence for the evaluation of outcomes
and a need for further research in this area100.
Preliminary evidence exists that VBID may positively impact racial and ethnic disparities
in medication adherence and health outcomes103. One experimental study of VBID’s
impact on medication adherence following AMI found that full coverage without cost
sharing of β-blockers and statins for nonwhite participants was associated with a 35%
lower risk of readmission and a 70% decrease in healthcare spending103. Remarkably, full
coverage without cost sharing eliminated disparities in rates of adverse coronary events
between white and nonwhite participants104.
Clearly, VBID has an important role to play in facilitating utilization of high-value care
by patients and reducing access and outcomes disparities caused by differential ability to
pay. Early success in medication adherence may be transferable to devices, procedures,
and clinical services103. It is possible that VBID could be used to incentivize patients to
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select high-quality hospitals. However, sole focus on patient-level factors is likely
insufficient for broad system-level alignment around quality. As such, VBID should be
pursued in conjunction with other innovative payment and healthcare delivery strategies.
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5.3 Key Study Limitations
Although the cross-sectional nature of this study precluded inference regarding the
directionality of the observed association, it provided helpful initial information about the
potential to use public reporting to channel patients to higher quality providers.
Other study limitations included hospital-level instead of patient-level analysis, the use of
a discrete set of performance measures for fee-for-service Medicare beneficiaries only,
and low or uneven use of performance scores by patients. Further research using data at
the patient level, additional performance measures (e.g. patient satisfaction), and younger
patient populations would provide additional insights.
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6.0 Conclusion
In conclusion, the results of this study demonstrated a statistically significant association
with a modest effect size between performance score and market share for hip and knee
replacement and AMI mortality. These results support efforts to (a) improve patients’
ability to choose where they receive their care and (b) improve the capacity or geographic
accessibility of high-quality facilities.
Value-based payment and healthcare delivery models are essential efforts to advance the
alignment of hospital quality and market share given their incentives around clinical
outcomes. However, a renewed focus on health equity must be central to these efforts as
early evidence suggests that some innovative value-based healthcare delivery and
payment models may disincentivize care for complex patient and worsen health access
and outcome disparities.

33

7.0 Images, Tables, and Figures
In order of appearance
Image 1: Screenshots from Hospital Care Compare

Source: Hospital Care Compare 2022105
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Table 1: Predicted market share <0% when using a simple linear model
# of Hospitals
% of Hospitals
Hip & Knee Complication
324
12.20%
AMI Mortality
316
14.60%
CABG Mortality
39
4%
AMI Readmission
294
14.80%
CABG Readmission
38
3.90%
Note: None of the hospitals had predicted market share >100%.
Figure 1: Market share predictions, when using a simple linear model
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Table 2: Full regression results with covariates, adjusted

Score
Beds – Second Tercile (ref:
first tercile)
Beds – Third Tercile (ref:
first tercile)
Market Concentration
Binomial – Unconcentrated
(ref: Concentrated)
Hospital Type - Critical
Access (ref: acute care)
Hospital Ownership –
Physician Ownership
(ref: government)
Hospital Ownership –
Voluntary non-profit
Teaching Status – Any
Teaching (ref: no teaching)
Hospital Region – Midwest
(ref: northeast)
Hospital Region – South
(ref: northeast)
Hospital Region – West
(ref: northeast)
HRR Population – Second
Tercile (ref: first tercile)
HRR Population – Third
Tercile (ref: first tercile)

AMI
Readmission
-1.68 (-3.1 to -0.25;
P=0.02)
0.09 (0.06 to 0.13;
P<.001)
0.18 (0.14 to 0.22;
P<.001)

AMI
Mortality
-0.85 (-2.07 to 0.38;
P=0.17)
0.09 (0.06 to 0.12;
P<.001)
0.18 (0.14 to 0.21;
P<.001)

CABG
Readmission
-0.49 (-2.49 to 1.52;
P=0.63)
0.05 (-0.01 to 0.11;
P=0.13)
0.14 (0.07 to 0.22;
P<.001)

CABG
Mortality
-1.24 (-4.4 to 1.93;
P=0.44)
0.05 (-0.01 to 0.12;
P=0.1)
0.14 (0.07 to 0.22;
P<.001)

Hip/Knee
Complication
-4.22 (-6.56 to 1.88; P<.001)
0.03 (0 to 0.06;
P=0.03)
0.1 (0.07 to 0.13;
P<.001)

-0.07 (-0.12 to 0.02; P=0.01)
-0.1 (-0.26 to 0.06;
P=0.22)

-0.07 (-0.12 to 0.02; P=0)
-0.1 (-0.19 to 0;
P=0.04)

-0.14 (-0.24 to 0.04; P=0.01)

-0.12 (-0.22 to 0.02; P=0.02)

-0.05 (-0.09 to 0.01; P=0.01)
-0.07 (-0.1 to -0.03;
P<.001)

0 (-0.06 to 0.06;
P=0.96)
0 (-0.04 to 0.05;
P=0.92)
0.01 (-0.04 to 0.06;
P=0.63)
-0.01 (-0.05 to 0.04;
P=0.79)
-0.01 (-0.06 to 0.04;
P=0.79)
0.02 (-0.03 to 0.07;
P=0.47)
-0.14 (-0.2 to -0.09;
P<.001)
-0.19 (-0.25 to 0.12; P<.001)

0 (-0.06 to 0.05;
P=0.85)
0.01 (-0.04 to 0.05;
P=0.74)
0 (-0.05 to 0.04;
P=0.96)
0.01 (-0.03 to 0.05;
P=0.62)
0.01 (-0.03 to 0.06;
P=0.66)
0.05 (0 to 0.1;
P=0.05)
-0.12 (-0.17 to 0.07; P<.001)
-0.16 (-0.23 to -0.1;
P<.001)

-0.03 (-0.14 to 0.08;
P=0.56)
-0.01 (-0.1 to 0.08;
P=0.78)
0.01 (-0.07 to 0.1;
P=0.76)
-0.08 (-0.17 to 0.01;
P=0.09)
-0.05 (-0.15 to 0.05;
P=0.34)
0.03 (-0.07 to 0.13;
P=0.57)
-0.32 (-0.4 to -0.24;
P<.001)
-0.42 (-0.51 to 0.32; P<.001)

-0.03 (-0.14 to 0.07;
P=0.54)
-0.01 (-0.1 to 0.08;
P=0.82)
0.01 (-0.07 to 0.09;
P=0.84)
-0.07 (-0.16 to 0.02;
P=0.12)
-0.04 (-0.14 to 0.06;
P=0.43)
0.03 (-0.07 to 0.13;
P=0.51)
-0.32 (-0.4 to -0.24;
P<.001)
-0.42 (-0.52 to 0.32; P<.001)

0.01 (-0.03 to 0.06;
P=0.53)
0.01 (-0.02 to 0.05;
P=0.43)
0.01 (-0.04 to 0.05;
P=0.77)
0 (-0.04 to 0.03;
P=0.86)
0 (-0.04 to 0.04;
P=0.92)
0.02 (-0.03 to 0.06;
P=0.49)
-0.11 (-0.16 to 0.07; P<.001)
-0.15 (-0.2 to -0.1;
P<.001)
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HRR Percent Non-White –
Second Tercile
0.01 (-0.03 to 0.05;
(ref: first tercile)
P=0.61)
HRR Percent Non-White –
Third Tercile
0 (-0.05 to 0.04;
(ref: first tercile)
P=0.84)
HRR Percent Rural – Second
Tercile
0.02 (-0.02 to 0.06;
(ref: first tercile)
P=0.29)
HRR Percent Rural – Third
Tercile
0.04 (0 to 0.09;
(ref: first tercile)
P=0.04)
HRR Percent Less than HS
Education – Second Tercile
-0.01 (-0.05 to 0.03;
(ref: first tercile)
P=0.6)
HRR Percent Less than HS
Education – Third Tercile
0 (-0.05 to 0.05;
(ref: first tercile)
P=0.93)
HRR Percent Below Federal
Poverty Line – Second
Tercile
-0.01 (-0.06 to 0.03;
(ref: first tercile)
P=0.5)
HRR Percent Below Federal
Poverty Line – Third Tercile
-0.01 (-0.06 to 0.03;
(ref: first tercile)
P=0.58)
Notes: Marginal effect, % (95% CI)

0.01 (-0.02 to 0.05;
P=0.5)

0 (-0.07 to 0.07;
P=0.98)

0 (-0.07 to 0.07;
P=0.95)

0.02 (-0.01 to 0.05;
P=0.2)

0 (-0.04 to 0.04;
P=0.91)

0.03 (-0.05 to 0.11;
P=0.46)

0.03 (-0.05 to 0.11;
P=0.53)

0.02 (-0.01 to 0.06;
P=0.24)

0.02 (-0.02 to 0.06;
P=0.25)

0.02 (-0.05 to 0.09;
P=0.6)

0.02 (-0.05 to 0.1;
P=0.54)

0.01 (-0.03 to 0.04;
P=0.71)

0.05 (0.01 to 0.09;
P=0.02)

0.05 (-0.03 to 0.13;
P=0.25)

0.05 (-0.03 to 0.13;
P=0.25)

0.02 (-0.02 to 0.05;
P=0.39)

-0.01 (-0.05 to 0.03;
P=0.54)

-0.03 (-0.11 to 0.04;
P=0.41)

-0.03 (-0.1 to 0.04;
P=0.42)

0 (-0.04 to 0.03;
P=0.78)

0 (-0.05 to 0.04;
P=0.87)

-0.05 (-0.14 to 0.04;
P=0.32)

-0.05 (-0.14 to 0.04;
P=0.3)

0 (-0.04 to 0.05;
P=0.82)

-0.01 (-0.05 to 0.03;
P=0.58)

-0.04 (-0.12 to 0.03;
P=0.24)

-0.05 (-0.12 to 0.03;
P=0.21)

-0.02 (-0.05 to 0.01;
P=0.26)

-0.01 (-0.06 to 0.03;
P=0.51)

-0.03 (-0.11 to 0.05;
P=0.45)

-0.03 (-0.11 to 0.05;
P=0.44)

-0.01 (-0.05 to 0.02;
P=0.5)
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Table 3: Markets, hospitals, and volume by presence of at least 1 “Better than national average” hospital within a market
Measure
30-Day AMI
Readmission Rate
30-Day AMI
Mortality Rate
30-Day CABG
Readmission Rate
30-Day CABG
Mortality Rate
Hip and Knee
Complication
Rate

Better than National Average
Hospital within HRR?
Single Hospital HRR
No
Yes
Single Hospital HRR
No
Yes
Single Hospital HRR
No
Yes
Single Hospital HRR
No
Yes
Single Hospital HRR
No
Yes

HRR Count (%)
28 (9.15%, n=306)
261 (85.29%, n=306)
17 (5.56%, n=306)
20 (6.54%, n=306)
263 (85.95%, n=306)
23 (7.52%, n=306)
84 (27.54%, n=305)
216 (70.82%, n=305)
5 (1.64%, n=305)
83 (27.21%, n=305)
211 (69.18%, n=305)
11 (3.61%, n=305)
6 (1.96%, n=306)
245 (80.07%, n=306)
55 (17.97%, n=306)
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Hospital Count (%)
28 (1.39%, n=2009)
1850 (92.09%, n=2009)
131 (6.52%, n=2009)
20 (0.91%, n=2186)
1812 (82.89%, n=2186)
354 (16.19%, n=2186)
84 (8.59%, n=978)
877 (89.67%, n=978)
17 (1.74%, n=978)
83 (8.41%, n=987)
818 (82.88%, n=987)
86 (8.71%, n=987)
6 (0.22%, n=2682)
1981 (73.86%, n=2682)
695 (25.91%, n=2682)

Volume Total (%)
11398 (2.52%, n=453064)
410129 (90.52%, n=453064)
31537 (6.96%, n=453064)
7466 (1.69%, n=441318)
361012 (81.8%, n=441318)
72840 (16.51%, n=441318)
13043 (10.12%, n=128898)
112342 (87.16%, n=128898)
3513 (2.73%, n=128898)
13408 (10.1%, n=132696)
105242 (79.31%, n=132696)
14046 (10.59%, n=132696)
4498 (0.48%, n=943537)
639554 (67.78%, n=943537)
299485 (31.74%, n=943537)

Table 4: Markets, hospitals, and volume by HRR hospital rating composition category
Measure

30-Day AMI
Readmission Rate

30-Day AMI
Mortality Rate

30-Day CABG
Readmission Rate

30-Day CABG
Mortality Rate

Hip and Knee
Complication
Rate

HRR Hospital Rating
Composition Category
Single Hospital
Only Average
Average & Worse
Average & Better
Worse, Average, & Better
Single Hospital
Only Average
Average & Worse
Average & Better
Single Hospital
Only Average
Average & Worse
Average & Better
Single Hosptial
Only Average
Only Worse
Average & Worse
Average & Better
Worse, Average, & Better
Single Hospital
Only Average
Average & Worse
Average & Better
Worse, Average, & Better

HRR Count (%)
28 (9.15%, n=306)
255 (83.33%, n=306)
6 (1.96%, n=306)
16 (5.23%, n=306)
1 (0.33%, n=306)
20 (6.54%, n=306)
247 (80.72%, n=306)
16 (5.23%, n=306)
23 (7.52%, n=306)
84 (27.54%, n=305)
204 (66.89%, n=305)
12 (3.93%, n=305)
5 (1.64%, n=305)
83 (27.21%, n=305)
202 (66.23%, n=305)
1 (0.33%, n=305)
8 (2.62%, n=305)
10 (3.28%, n=305)
1 (0.33%, n=305)
6 (1.96%, n=306)
211 (68.95%, n=306)
34 (11.11%, n=306)
47 (15.36%, n=306)
8 (2.61%, n=306)
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Hospital Count (%)
28 (1.39%, n=2009)
1732 (86.21%, n=2009)
118 (5.87%, n=2009)
114 (5.67%, n=2009)
17 (0.85%, n=2009)
20 (0.91%, n=2186)
1650 (75.48%, n=2186)
162 (7.41%, n=2186)
354 (16.19%, n=2186)
84 (8.59%, n=978)
775 (79.24%, n=978)
102 (10.43%, n=978)
17 (1.74%, n=978)
83 (8.41%, n=987)
777 (78.72%, n=987)
2 (0.2%, n=987)
39 (3.95%, n=987)
81 (8.21%, n=987)
5 (0.51%, n=987)
6 (0.22%, n=2682)
1498 (55.85%, n=2682)
483 (18.01%, n=2682)
496 (18.49%, n=2682)
199 (7.42%, n=2682)

Volume Total (%)
11398 (2.52%, n=453064)
388191 (85.68%, n=453064)
21938 (4.84%, n=453064)
27869 (6.15%, n=453064)
3668 (0.81%, n=453064)
7466 (1.69%, n=441318)
328947 (74.54%, n=441318)
32065 (7.27%, n=441318)
72840 (16.51%, n=441318)
13043 (10.12%, n=128898)
98703 (76.57%, n=128898)
13639 (10.58%, n=128898)
3513 (2.73%, n=128898)
13408 (10.1%, n=132696)
98702 (74.38%, n=132696)
245 (0.18%, n=132696)
6295 (4.74%, n=132696)
12392 (9.34%, n=132696)
1654 (1.25%, n=132696)
4498 (0.48%, n=943537)
478909 (50.76%, n=943537)
160645 (17.03%, n=943537)
221998 (23.53%, n=943537)
77487 (8.21%, n=943537)

8.0 Maps
Figure 2: HRR Facility Rating Variation: Mortality AMI

Figure 3: HRR Facility Rating Variation: Readmission AMI

40

Figure 4: HRR Facility Rating Variation: CABG Mortality

Figure 5: HRR Facility Rating Variation: CABG Readmission
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Figure 6: HRR Facility Rating Variation: Hip & Knee Replacement
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